查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600613

临床试验市场：依设计、阶段、适应症划分 - 2025-2030 年全球预测

Clinical Trials Market by Design (Interventional Study, Observational Study), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年临床试验市值为383亿美元，预计到2024年将达到417.8亿美元，复合年增长率为9.16%，预计到2030年将达到707.8亿美元。

临床试验市场涵盖人类药物、设备和治疗测试的所有阶段，并作为开发平臺的关键组成部分，确保新治疗方法在向公众发布之前的有效性和安全性。临床试验的需求源于为监管核准提供必要资料并透过创新解决方案对抗不断发展的疾病的需要。这些研究在製药、生物技术和医疗设备业有着广泛的应用，最终用途是医院、研究机构和委外研发机构(CRO)。显着影响成长的因素包括生物医学研究的进步、慢性病的增加，以及人工智慧和机器学习等技术在试验设计和资料收集中的整合。市场参与企业的新商机集中在分散临床试验（DCT）上，它利用远端医疗和行动医疗技术来改善病患招募和保留。然而，市场成长受到高成本、严格的监管要求、道德问题以及管理复杂试验设计的后勤挑战的限制。为了利用创新和研究，相关人员将专注于整合数位健康工具，以简化参与者的参与，并探索允许根据中间结果进行即时修改的自适应试验设计。用于病患招募和现实世界证据收集的创新平台可以提高试验效率和结果。此外，製药公司、CRO 和技术提供者之间的伙伴关係可以促进试验管理方面的资源和专业知识共用。竞争格局由全球和区域参与者组成，每位参与者都利用其独特的能力来扩大其市场范围。对这个充满活力的市场的洞察表明，随着精准医学、基因组研究和特种药物的发展势头持续增长。加强临床试验透明度和以患者为中心，同时策略性地驾驭监管环境，可以为临床试验领域的未来成长提供强有力的道路。

主要市场统计
基准年[2023] 383亿美元
预测年份 [2024] 417.8亿美元
预测年份 [2030] 707.8亿美元
复合年增长率（%） 9.16%

市场动态：揭示快速发展的临床试验市场的关键市场洞察

供需的动态交互作用正在改变临床试验市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于疾病盛行率上升和 CRO 整合而改善临床试验
    • 医药及生技製药产业研发费用增加
    • 越来越关注学名药和生技药品的开发和商业化
  • 市场限制因素
    • 药物开发成本增加，临床研究专业人员短缺
  • 市场机会
    • 越来越关注药物开发和以患者为中心的临床试验
    • 临床试验全球化与法规统一的进展
  • 市场挑战
    • 严格的病患登记规定和跨境物流挑战

波特五力：驾驭临床试验市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解临床试验市场的外部影响

外部宏观环境因素在塑造临床试验市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解临床试验市场的竞争状况

对临床试验市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵临床试验市场供应商的绩效评估

FPNV定位矩阵是评估临床试验市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製临床试验市场的成功之路

临床试验市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 透过 CRO 整合增加疾病发生率并改善临床试验
      • 医药及生技製药产业研发费用增加
      • 专注于学名药和生技药品的开发和商业化
    • 抑制因素
      • 药物开发成本增加和临床研究专业人员短缺
    • 机会
      • 加强对药物开发的重视，将临床试验转向以病人为中心
      • 临床试验的全球化和监管协调的进展
    • 任务
      • 严格的病患登记规定和跨境物流挑战
  • 市场区隔分析
    • 设计：介入性和观察性临床试验设计对于优化治疗效果、风险和安全性评估的重要性
    • 阶段：分阶段实施临床试验，监测药物代谢并收集初步资料
    • 适应症：一些建议对慢性疾病、心血管疾病和其他有害疾病进行适当治疗方法和药物治疗的适应症。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 临床试验市场：设计

  • 干预研究
    • 自我调整临床试验
    • 非随机对照试验
    • 随机对照试验
  • 观察性研究
    • 病例对照研究
    • 队列研究
    • 横断面研究
    • 生态学研究

第七章 临床试验市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第八章 依适应症分類的临床试验市场

  • 自体免疫/发炎
  • 心血管
  • 中枢神经系统状况
  • 糖尿病
  • 感染疾病
  • 肥胖
  • 肿瘤学
  • 疼痛管理

第九章美洲临床试验市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太临床试验市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲临床试验市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 柯尔伯格收购全球临床试验的多数股权
    • Arcanza 和 Reveles 合作扩大代表性不足社区的综合临床研究
    • 百时美施贵宝和杨森合作开始关键的 3 期 Librexia 临床试验计划，评估口腔因子 XIa 抑制剂 Milbekian
  • 战略分析和建议

公司名单

  • ProPharma Group Holdings, LLC
  • Charles River Laboratories International, Inc.
  • Accell Clinical Research, LLC
  • Congenix LLP
  • Parexel International Corporation
  • Qiagen NV
  • SGS SA
  • Bristol-Myers Squibb Company
  • Bio-Rad Laboratories, Inc.
  • SIRO Clinpharm Private Limited
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Clinipace
  • Atlant Clinical Ltd.
  • Quipment SAS
  • Labcorp
  • IQVIA Holdings, Inc.
  • Becton, Dickinson and Company
  • Merck KGaA
  • Eli Lilly and Company
  • Syneos Health, Inc.
  • Wuxi AppTec Inc.
  • Thermo Fisher Scientific Inc.
  • Icon PLC
  • Sartorius AG
  • Illumina, Inc
Product Code: MRR-434CCDA05152

The Clinical Trials Market was valued at USD 38.30 billion in 2023, expected to reach USD 41.78 billion in 2024, and is projected to grow at a CAGR of 9.16%, to USD 70.78 billion by 2030.

The clinical trials market encompasses all phases of drug, device, and treatment testing on human subjects, serving as a critical component in the development pipeline that assures the efficacy and safety of new therapies before they reach the public. The necessity of clinical trials arises from the need to combat evolving diseases with innovative solutions, providing vital data for regulatory approvals. These trials are broadly applicable across pharmaceutical, biotechnology, and medical device industries, with end-use in hospitals, research institutes, and contract research organizations (CROs). Significant growth influencers include advancements in biomedical research, increased prevalence of chronic diseases, and technological integration such as AI and machine learning in trial design and data collection. Emerging opportunities for market participants center around decentralized clinical trials (DCTs), which utilize telehealth and mobile health technologies to improve patient recruitment and retainment. However, market growth is constrained by high costs, stringent regulatory requirements, and ethical issues, along with logistical challenges in managing complex trial designs. To capitalize on innovation and research, stakeholders could focus on integrating digital health tools to streamline participant engagement or exploring adaptive trial designs that permit real-time modifications based on interim results. Innovative platforms for patient recruitment and real-world evidence collection can enhance trial efficiency and outcomes. Furthermore, developing partnerships between pharmaceutical companies, CROs, and technology providers can facilitate the sharing of resources and expertise in trial management. The competitive landscape comprises both global and regional players, each leveraging unique capabilities to expand market reach. Insight into this dynamic market suggests continual growth as precision medicine, genomic studies, and specialty pharmaceuticals gain momentum. Strategically navigating regulatory landscapes while enhancing trial transparency and patient centricity can offer a robust pathway for future growth in the clinical trials sector.

KEY MARKET STATISTICS
Base Year [2023] USD 38.30 billion
Estimated Year [2024] USD 41.78 billion
Forecast Year [2030] USD 70.78 billion
CAGR (%) 9.16%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Trials Market

The Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diseases and improved clinical trials due to CRO consolidation
    • Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
    • Increased focus on the development and commercialization of generics and biologics
  • Market Restraints
    • Increased cost of drug development and lack of skilled clinical research professional
  • Market Opportunities
    • Increased focus on drug development and shift towards patient-centric clinical trials
    • Growing globalization of clinical trials and harmonization of regulations
  • Market Challenges
    • Stringent regulations for patient enrollment and cross-border logistics challenges

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Trials Market

A detailed market share analysis in the Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Trials Market

A strategic analysis of the Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include ProPharma Group Holdings, LLC, Charles River Laboratories International, Inc., Accell Clinical Research, LLC, Congenix LLP, Parexel International Corporation, Qiagen NV, SGS S.A., Bristol-Myers Squibb Company, Bio-Rad Laboratories, Inc., SIRO Clinpharm Private Limited, Novo Nordisk A/S, Pfizer Inc., Clinipace, Atlant Clinical Ltd., Quipment SAS, Labcorp, IQVIA Holdings, Inc., Becton, Dickinson and Company, Merck KGaA, Eli Lilly and Company, Syneos Health, Inc., Wuxi AppTec Inc., Thermo Fisher Scientific Inc., Icon PLC, Sartorius AG, and Illumina, Inc.

Market Segmentation & Coverage

This research report categorizes the Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Design, market is studied across Interventional Study and Observational Study. The Interventional Study is further studied across Adaptive Clinical Trial, Non-randomized Control Trial, and Randomized Control Trial. The Observational Study is further studied across Case Control Study, Cohort Study, Cross Sectional Study, and Ecological Study.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Indication, market is studied across Autoimmune/Inflammation, Cardiovascular, CNS condition, Diabetes, Infectious Diseases, Obesity, Oncology, and Pain management.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diseases and improved clinical trials due to CRO consolidation
      • 5.1.1.2. Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
      • 5.1.1.3. Increased focus on the development and commercialization of generics and biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Increased cost of drug development and lack of skilled clinical research professional
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on drug development and shift towards patient-centric clinical trials
      • 5.1.3.2. Growing globalization of clinical trials and harmonization of regulations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for patient enrollment and cross-border logistics challenges
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Design: Importance of interventional and observational clinical trial design to optimize assessment of treatment efficacy, risk, and safety
    • 5.2.2. Phase: clinical trial phases in for monitoring drug metabolism and gathering initial data
    • 5.2.3. Indication: Several indications suggesting suitable treatments and medications for chronic, cardiovascular, and other harmful diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Trials Market, by Design

  • 6.1. Introduction
  • 6.2. Interventional Study
    • 6.2.1. Adaptive Clinical Trial
    • 6.2.2. Non-randomized Control Trial
    • 6.2.3. Randomized Control Trial
  • 6.3. Observational Study
    • 6.3.1. Case Control Study
    • 6.3.2. Cohort Study
    • 6.3.3. Cross Sectional Study
    • 6.3.4. Ecological Study

7. Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/Inflammation
  • 8.3. Cardiovascular
  • 8.4. CNS condition
  • 8.5. Diabetes
  • 8.6. Infectious Diseases
  • 8.7. Obesity
  • 8.8. Oncology
  • 8.9. Pain management

9. Americas Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Kohlberg Acquires Majority Stake in Worldwide Clinical Trials
    • 12.3.2. Alcanza and Reveles Partner to Expand Inclusive Clinical Research in Underrepresented Communities
    • 12.3.3. The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ProPharma Group Holdings, LLC
  • 2. Charles River Laboratories International, Inc.
  • 3. Accell Clinical Research, LLC
  • 4. Congenix LLP
  • 5. Parexel International Corporation
  • 6. Qiagen NV
  • 7. SGS S.A.
  • 8. Bristol-Myers Squibb Company
  • 9. Bio-Rad Laboratories, Inc.
  • 10. SIRO Clinpharm Private Limited
  • 11. Novo Nordisk A/S
  • 12. Pfizer Inc.
  • 13. Clinipace
  • 14. Atlant Clinical Ltd.
  • 15. Quipment SAS
  • 16. Labcorp
  • 17. IQVIA Holdings, Inc.
  • 18. Becton, Dickinson and Company
  • 19. Merck KGaA
  • 20. Eli Lilly and Company
  • 21. Syneos Health, Inc.
  • 22. Wuxi AppTec Inc.
  • 23. Thermo Fisher Scientific Inc.
  • 24. Icon PLC
  • 25. Sartorius AG
  • 26. Illumina, Inc

LIST OF FIGURES

  • FIGURE 1. CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023